|
|
Naltrexone |
|
Vaxjo ID |
350 |
|
Vaccine Adjuvant Name |
Naltrexone |
|
Adjuvant VO ID |
VO_0005661
|
|
Description |
Naltrexone is described as an efficient adjuvant capable of inducing Th1 immune responses, specifically increasing IFN-纬 and IgG2a production, and enhancing the proliferative response of splenocytes/lymphocytes. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Preparation |
Used in immunization experiments by immunizing mice with NLT adjuvant and *F. hepatica* E/S antigens. |
|
Function |
we examined immune augmenting capacities of an emerging adjuvant, Naltrexone, against Fasciola hepatica infection in BALB/c mice. Negates the effects of exogenous opioids through competitive binding with opioid receptors; exhibits strong affinity for µ-opioid receptors in the central nervous system; high affinity, but also partial agonistic activity towards κ receptors in the brain and spinal cord; minor affinity for δ receptors in the spinal cord and peripheral nervous system. [PMC10968813] |
| References |
Azizi et al., 2018: Azizi H, Mirzaeei H, Nasiri AA, Bazi A, Mirzapour A, Khatami M, Nahavandi KH, Azimi A, Yaghoobi H. Naltrexone; as an efficient adjuvant in induction of Th1 immunity and protection against Fasciola hepatica infection. Experimental parasitology. 2018; 189; 66-71. [PubMed: 29729492].
Ciwun et al., 2024: Ciwun M, Tankiewicz-Kwedlo A, Pawlak D. Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy. Cancers. 2024; 16(6); . [PubMed: 38539570].
|
|
